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Abstract
In a continuing study of curcumin analogs as potential drug candidates to treat prostate cancer at both
androgen-dependent and androgen-refractory stages, we designed and synthesized over 40 new
analogs classified into four series: monophenyl analogs (series A), heterocycle-containing analogs
(series B), analogs bearing various substituents on the phenyl rings (series C) and analogs with
various linkers (series D). These new compounds were tested for cytotoxicity against two human
prostate cancer cell lines, androgen-dependent LNCaP and androgen-independent PC-3.
Antiandrogenic activity was also evaluated in LNCaP cells and PC-3 cells transfected with wild-type
androgen receptor. Ten compounds possessed potent cytotoxicity against both LNCaP and PC-3
cells; seven only against LNCaP; and one solely against PC-3. This study established an advanced
structure-activity relationship (SAR), and these correlations will guide the further design of new
curcumin analogs with better anti-prostate cancer activity.
Introduction
Prostate cancer is the most common cancer among males of Western countries,2 and is a
complex heterogeneous disease that acts differently in different men. The real cause of prostate
cancer is still unknown. However, androgen and the androgen receptor (AR) are postulated to
play crucial roles in the development of prostate cancer.3 The current treatment for prostate
cancer is a combination of surgery, radiation and chemotherapy. The therapeutic agents used
clinically include steroidal antiandrogens, such as cyproterone acetate, and nonsteroidal
antiandrogens, such as flutamide and bicalutamide. The steroidal antiandrogens possess partial
agonistic activity and overlapping effects with other hormonal systems, leading to many
complications including severe cardiovascular problems, gynecomastia, loss of libido and
erectile dysfunction.4-6 The nonsteroidal antiandrogens show fewer side effects and have
improved oral bioavailability; therefore, they are favored over the steroidal antiandrogens.
However, antiandrogen withdrawal syndrome has been discovered in patients receiving
nonsteroidal antiandrogens for several months.7,8 Long-term drug usage probably leads to
mutation of the AR, and the nonsteroidal antiandrogens now exhibit agonistic activity to the
mutant AR.9 In addition, the clinically available antiandrogens are unable to kill prostate cancer
cells, and within one to three years of drug administration, the cancer usually develops into an
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androgen-refractory stage, which is not curable. Therefore, it is urgent to develop new classes
of anti-prostate cancer drugs.
Prostate cancer incidence is much lower in Asian than in Western countries,10 possibly due
to differences in diet. Turmeric is a spice and medicine much more highly consumed in Asian
countries such as India, Thailand, China and Japan. Curcumin (1) is the major constituent in
the rhizome of Curcuma longa (Zingiberaceae), commonly named turmeric. Over the last few
decades, 1 has been studied fairly extensively and has been found to have various biological
properties including anti-inflammatory,11 anti-oxidant,12 anti-HIV,13 chemo-preventive,14
and anticancer15 effects in several cell types. In our laboratory, we used 1 as a lead compound
to design and synthesize 1-analogs as a new class of potential antiandrogenic agents for the
treatment of prostate cancer.16-18 Certain 1-analogs showed antiandrogenic activity in human
prostate cancer cells, and two potent antiandrogens previously developed in our laboratory,
dimethylated curcumin (DMC, 2) and 4-ethoxycarbonylethyl curcumin (ECECur, 3), are
currently under in vivo investigation. Most recently, we found that the curcumin analog 4
possesses potent antiandrogenic activity. From our prior studies, a preliminary antiandrogenic
structure-activity relationship (SAR) was established. In a continuing study, we have now
prepared four series of new 1-analogs including monophenyl curcumin analogs (series A),
heterocycle-containing curcumin analogs (series B), curcumin analogs bearing various
substituents on the phenyl rings (series C) and curcumin analogs with various linkers (series
D). These new 1-analogs were evaluated in cytotoxicity and antiandrogenic assays in two
human prostate cancer cell lines, LNCaP and PC-3. Based on the structures and anti-prostate
cancer activities of the new 1-analogs, a more detailed SAR has been formulated. This advanced
SAR better reveals the structural features of 1-analogs responsible for the cytotoxic as well as
antiandrogenic activities in human prostate cancer cells. This information will guide our
optimization of 1-analogs with better pharmacological profiles as potential drug candidates for
the treatment of prostate cancer.
Chemistry
The general synthetic scheme for series A is shown in Scheme 1. To avoid the aldol
condensation taking place at both terminals of 2,4-pentanedione, excess pentanedione was used
in this reaction.19 Boric anhydride was first added to form a complex with 2,4-pentanedione.
The aim of this complexation is to protect C-3 from Knoevenagel condensation so that the
aldol condensation takes place at the terminal carbon.
The synthetic strategies for series B (heterocycle-containing curcumin analogs) and series C
(symmetric and asymmetric curcumin analogs with various substituents on the phenyl rings)
are shown in Scheme 2 and Scheme 3, respectively. The symmetric compounds were
synthesized by using Pederson's method.20 At least two equivalents of the aldehyde are needed
to ensure aldol condensation at both terminals of the dione. To prepare asymmetric compounds
having different aryl rings, a monoaryl intermediate was first prepared by using the method
shown in Scheme 1, and subsequently condensed with an appropriate second aldehyde to give
the target compounds.
The syntheses of series D with various linkers between the two phenyl rings are shown in
Schemes 4-9.
In the general synthesis of 1, 5-diphenyl-1, 4-pentadien-3-ones, one equivalent of acetone and
two equivalents of substituted benzaldehyde were treated with 0.25 M NaOH solution and 0.25
equivalent 25% aqueous solution of cetyltrimethylammonium bromide to afford the product
(Scheme 4).
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Curcumin analogs with an elongated linker were prepared by employing Pederson's synthetic
method.20 2,4-Pentanedione or ethyl 4-acetyl-5-oxohexanoate was reacted with 4-hydroxy-3-
methoxy-cinnamaldyhyde to give 35 or 36 as the target analog (Scheme 5).
Hydrogenation of DMC in the presence of 10% Pd/C gave the saturated analog 37 as the product
(Scheme 6). The partially saturated analog 38 has a hydroxy group in the linker instead of an
enol, and was prepared as shown in Scheme 7. 3,4-Dimethoxycinnamone and 3, 4-
dimethoxycinnamaldehyde were both prepared from 3,4-dimethoxybenzaldyhyde by
condensation with acetone and acetaldehyde, respectively. After treating 3,4-
dimethoxycinnamone with LDA at −78 °C, 3,4-dimethoxycinnamoaldehyde was added to
provide 38.21
To synthesize the imide curcumin analog (39), 3,4-dimethoxy cinnamic acid was first
converted to the acid chloride by treatment with thionyl chloride. Then, two equivalents of the
acid chloride were reacted with one equivalent of (Me3Si)2NH in the presence of triethylamine
to give the target product 39.22 (Scheme 8)
The syntheses of curcumin analogs 4, 40−45, 47 and 48, which have mono- or disubstitution
at C-4, have been described and discussed elsewhere.18 The preparation of 49 and 50 is shown
in Scheme 9. 4-Methyl DMC (49) was prepared by using the methodology shown in Scheme
2 and then fluorinated by SelectFluor™ under basic conditions to give 4-fluoro-4-methyl DMC
(50).23
Results and Discussion
The target compounds were tested for cytotoxicity against two human prostate cancer cell lines,
LNCaP and PC-3. The LNCaP cell line is an androgen-dependent human prostate cancer cell
line that expresses mutant AR, and the PC-3 cell line is an androgen-independent human
prostate cancer cell line that does not express functional AR. The antiandrogenic activity of
these 1-analogs was examined in LNCaP cells and PC-3 cells transfected with wild type AR.
The seven monophenyl analogs (5−11) did not exhibit significant cytotoxicity in either LNCaP
or PC-3 cells (Table 1A). The absence of one phenyl ring in the curcumin skeleton apparently
results in decreased cytotoxicity, indicating that both phenyl rings must be present to retain
cytotoxicity against human prostate cancer cells.
In addition, none of the four heterocycle-containing series B analogs (12−15) showed
significant cytotoxicity in either LNCaP or PC-3 cells (Table 1.B). These results suggest that
replacing the phenyl ring(s) with 5-membered-heterocyle(s) will not improve the desired
activity. This information will guide us to design new 1-analogs with the phenyl rings intact.
Series C contains symmetric and asymmetric curcumin analogs with various substituents on
the phenyl rings. None of these newly synthesized analogs showed better cytotoxicity than
DMC (2), which has IC50 values of 1.1 μM (PC-3) and 1.3 μM (LNCaP) (Table 1.C).
Compound 19, which has 3’,4’,6’-dimethoxy substitution on both phenyl rings, was active
against both human prostate cancer cell lines. Compounds 24 and 25, which have 3’,5’-
dimethoxy-4’-hydroxy and 3’-methyl-4’-hydroxyl substituted phenyl rings, respectively, were
active against androgen-dependent LNCaP cells. Among the five asymmetric analogs, 27 and
31 also exhibited activity against LNCaP cells. Both compounds have 3’,4’-dimethoxy
substitution on one phenyl ring and 3’-methoxy-4’-hydroxy substitution on the other (Table
1.D). In addition, 31 has an ethoxycarbonylethyl side chain at position C-4 of the linker. Thus,
symmetry is not a vital requirement for selective cytotoxic activity. The common features of
the phenyl rings of these active compounds are as follows. 1) The C-2’ positions should be
unsubstituted. 2) The C-3’ positions should be substituted. However, while methoxy or methyl
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substituents are favorable, hydroxy groups are not favorable at these positions. 3) The C-4’
positions should also be substituted. The substituents can either be two methoxy groups, two
hydroxy groups or one methoxy and one hydroxy. Ethoxy and isoprenyl substituents are not
favorable at these positions. 4) Except for 24, most of these synthesized compounds are
unsubstituted at the C-5’ position. However, 24 has C-5’ methoxy substituents, and it was
active in LNCaP cells. 5) Most of the new analogs have no substitution on the C-6’ positions.
An exception is 19, which has methoxy substituents on C-6’, and retained activity in both cell
lines. Additional investigation will be needed to probe what functional groups can be
accommodated at the C-5’ and C-6’ positions to keep or even enhance the activity of curcumin
analogs.
With 3’,4’-dimethoxy or 3’-methoxy-4’-hydroxy substituents on the phenyl rings, compounds
having a 1,4-pentadien-3-one linker (e.g. 32 and 33) showed significant cytotoxicity against
both human prostate cancer cell lines (Table 1E). However, 34, an analog that also possesses
a 1,4-pentadien-3-one linker but has 2,4-dimethoxy substituted phenyl rings, was inactive.
These results once again confirm the importance of 3’,4’-disubstitution on the phenyl rings.
Curcumin analogs 35 and 36 have elongated linkers (11 carbons) connecting the 3’-
methoxy-4’-hydroxy phenyl rings. Compound 35 was not cytotoxic in either prostate cancer
cell line, while 36 showed cytotoxicity against LNCaP cells (IC50 3.1 μM), but activity against
PC-3 cells was not significant. Overall, compared with 1 and 3, the cytotoxicity of 35 and 36
decreased. Thus, elongation of the linker did not improve the cytotoxic activity of 1-analogs
against prostate cancer cells. Compounds 37 (saturated DMC: 3-hydroxy-heptane-5-one
linker)and 38 (partially saturated DMC: 3-hydroxy-1,6-heptadien-5-one linker) were not
cytotoxic toward prostate cancer cells, suggesting that an unsaturated and conjugated linker,
such as the 3-hydroxy-1,4,6-heptatrien-5-one found in 1 and 2, is required for the bioactivity
of 1-analogs. When NH replaced the CH2 between the two carbonyl groups in a similar linking
group, the resulting imide analog (39) lost cytotoxicity against PC-3 cells but remained
cytotoxic against LNCaP cells with an IC50 of 2.2 μM. Compounds with both fluorine and
either a propionic ethyl ester or a methyl group at the middle (C-4) carbon (e.g. 47, 48, 50)
were not cytotoxic against either tested cell line. However, various unsaturated (acrylic ester,
acrylamide, acrylonitrile, allyl alcohol) mono-substitution at C-4 of the linker (e.g. 40, 42
−45) resulted in high cytotoxicity against both human prostate cancer cell lines. These analogs
were generally more potent than 1 and as potent as 2−4. From the bioassay results of Series D,
we can see that it is essential to design a proper linker connecting the substituted phenyl rings
in order to obtain potent anti-prostate cancer analogs. The best linkers discovered so far are 3-
hydroxy-1,4,6-heptatrien-5-one (the original curcumin linker), 1,4-pentadien-3-one (a shorter
linker) and several 4-mono-substituted 3-hydroxy-1,4,6-heptatrien-5-ones that are shown in
the structures of ECECur (3), 4, 40 and 42−45.
New 1-analogs also were evaluated in an anti-AR assay in LNCaP cells and PC-3 cells
transfected with wild-type AR. Table 2 shows the antiandrogenic activity of the most potent
compounds (3, 4, 40 and 44); the remaining analogs exhibited no or weak activity in the
antiandrogenic bioassay. All four potent compounds have similar phenyl substitutions, linking
groups, and side chains. Because the most cytotoxic compounds (42, 43 and 45) were inactive
in the anti-AR bioassay, they likely have mechanisms of action other than interrupting the AR
signaling pathway in human prostate cancer cells. Either with or without antiandrogenic
activity, these cytotoxic 1-analogs have potential to treat both androgen-dependent prostate
cancer and androgen-refractory prostate cancer.
An advanced SAR has been established on the basis of the structure information and
bioactivities of the newly synthesized 1-analogs discussed above. The following SAR
conclusions were made. 1) Biphenyl rings are required for the cytotoxic and antiandrogenic
activities. 2) The C-2’ positions of the phenyl rings should be unsubstituted. 3) The C-3’ and
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C-4’ positions should be substituted, with 3’,4’-dimethoxy and 3’-methoxy-4’-hydroxy
substituents on the phenyl rings found to be most favorable. Substitution at the C-5’ and C-6’
positions probably will not affect the cytotoxicity. 4) The length of the linker impacts the
cytotoxicity as well as antiandrogenic activity in human prostate cancer cells. Elongation of
the linker results in the loss of cytotoxicity and antiandrogenic activity. 5) An unsaturated and
conjugated linker is required for the cytotoxic and antiandrogenic activities. 6) Substitution at
the C-4 position of the linker is very crucial for improved anti-AR activity in this compound
class. Mono-substitution with proper side chains improved the cytotoxicity significantly.
Conclusions
In conclusion, we synthesized over 40 new 1-analogs and first examined their cytotoxicity
against androgen-dependent LNCaP and androgen-independent PC-3 human prostate cancer
cell lines. Ten compounds (2, 4, 19, 32, 33, 40 and 42−45) showed significant cytotoxicity
against both androgen-dependent LNCaP cells and androgen-independent PC-3 cells. Seven
compounds [1 (curcumin), 3 (ECECur), 24, 25, 27, 31 and 39] were cytotoxic only against
androgen-dependent LNCaP cells. Only one compound (49) was active against PC-3 cells but
inactive against LNCaP cells. The most potent antiandrogenic compounds were 3 (ECECur),
4, 40 and 44. Those analogs that were active in the cytotoxicity assay but inactive in the
antiandrogenic assay are presumed to act by a different mechanism other than interrupting the
AR signaling pathway. All active compounds are potential drug candidates for the treatment
of prostate cancer at the androgen-dependent or androgen-refractory stage. The study of their
mechanism(s) of action will be useful in exploring the causes of prostate cancer. In addition,
an advanced SAR has been established from this work. This extensive SAR information will
guide us to design optimized 1-analogs having better, selective anti-prostate cancer activity.
Experimental Section
Melting points were determined on a Fisher-Johns melting apparatus and are uncorrected. 1H
NMR spectra were recorded on a Varian Gemini-300 spectrometer. The chemical shifts are
presented in terms of ppm with TMS as the internal reference. MS spectra were recorded on
Agilent 1100 series LC/MS trap and API-3000 LC/MS/MS spectrometer. Column
chromatography was carried out on CombiFlash® Companion ™ (Isco, Inc.), and thin-layer
chromatography was performed on pre-coated silica gel or aluminum plates (Aldrich, Inc.).
Elemental analyses were performed by Atlantic Microlab Inc., Norcross, GA, and agreed with
theoretical values to within ± 0.4%.
Preparation of mono-phenyl analogs 5−11
To a solution of 2,4-pentanedione or 4-acetyl-5-oxo-hexanoate in EtOAc (3 eq) was added
boric anhydride (0.7 eq). The solution was stirred at 70 °C for 0.5 h. To the solution, the
aldehyde (1 eq) and tributyl borate (1 eq) were added. The mixture was stirred for 30 min. At
85 °C, butylamine (1 eq) dissolved in EtOAc was added dropwise over 15 min. The stirring
continued for 1 h at 100 °C. The mixture was then hydrolyzed by adding 1N HCl at 50 °C and
stirring for 0.5 h at 50 °C. The organic layer was separated, and the aqueous layer was extracted
with EtOAc. The combined organic layers were washed until neutral, dried over anhydrous
sodium sulfate. After removing the solvent in vacuo, the crude products were purified by flash
column chromatography eluting with a hexane-EtOAc gradient.
4-Hydroxy-6-(4-hydroxy-3-methoxyphenyl)-hexa-3,5-dien-2-one (5)
(from vanillin and 2,4-pentanedione) Yellow powder, 50% yield. mp 146 −147 °C (lit.24 146
−147 °C); ESI MS m/z 235.0 (M+H)+; 1H NMR (300 MHz, CDCl3): δ 2.16 (3H, s), 3.94 (3H,
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s), 5.63 (H, s), 6.33 (H, d, J= 15.9 Hz), 6.92 (H, d, J= 8.1 Hz), 7.01 (H, d, J= 1.8 Hz), 7.10 (H,
dd, J= 8.1 Hz, J= 1.8 Hz), 7.53 (H, d, J=15.9 Hz).
6-(3,4-Dimethoxyphenyl)-4-hydroxyhexa-3,5-dien-2-one (6)
(from 3,4-dimethoxybenzaldehyde and 2,4-pentanedione) 48% yield. mp 78−79 °C; ESI MS
m/z 249.0 (M+H)+; 1H NMR (300 MHz, CDCl3): δ 2.10 (3H, s), 3.92 (6H, s), 5.64 (H, s), 6.35
(H, d, J= 16.2 Hz), 6.87 (H, d, = 8.4 Hz), 7.04 (H, d, J= 1.8 Hz), 7.11 (H, dd, J= 8.4 Hz, J=
1.8 Hz), 7.55 (H, d, J=16.2 Hz).
4-Hydroxy-6-(3-hydroxy-4-methoxyphenyl)-hexa-3,5-dien-2-one (7)
(from 3-hydroxy-4-methoxybenzaldehyde and 2,4-pentanedione) 45% yield. mp 163−164 °C
(lit.24 160−162 °C); ESI MS m/z 233.2 (M-1)+; 1H NMR (300 MHz, CDCl3): δ 2.16 (3H, s),
3.93 (3H, s), 5.63 (H, s), 6.32 (H, d, J= 15.6 Hz), 6.85 (H, d, J= 8.7 Hz), 7.02 (H, dd, J= 8.7
Hz, J= 2.1 Hz), 7.14 (H, d, J= 2.1 Hz), 7.51 (H, d, J=15.6 Hz).
6-(2,4-Dimethoxyphenyl)-4-hydroxyhexa-3,5-dien-2-one (8)
(from 2,4-dimethoxybenzaldehyde and 2,4-pentanedione) 44% yield. mp 92−93 °C; ESI MS
m/z 249.0 (M+H)+; 1H NMR (300 MHz, CDCl3): δ 2.15 (3H, s), 3.85 (3H, s), 3.87 (3H,s), 5.63
(H, s), 6.48 (H, d, J= 15.9 Hz), 6.50 (H, d, J= 2.1 Hz), 6.51 (H, dd, J= 8.1 Hz, J= δ 2.1 Hz),
7.46 (H, d, J= 8.4 Hz), 7.84 (H, d, J=15.9 Hz). Anal. (C14H16O4·1/8 H2O) C, H.
4-Hydroxy-6-(2,3,4-trimethoxyphenyl)-hexa-3,5-dien-2-one (9)
(from 2,3,4-trimethoxybenzaldehyde and 2,4-pentanedione) 45% yield. mp 66−67 °C; ESI MS
m/z 279.2 (M+H)+; 1H NMR (300 MHz, CDCl3): δ 2.16 (3H, s), 3.88 (3H, s), 3.90 (3H, s),
3.92 (3H, s), 5.64 (H, s), 6.48 (H, d, J= 15.9 Hz), 6.70 (H, d, J= 8.7 Hz), 7.27 (H, d, J= 8.7
Hz), 7.79 (H, d, J=15.9 Hz). Anal. (C15H18O5) C, H.
4-Hydroxy-6-(2,4,5-trimethoxyphenyl)-hexa-3,5-dien-2-one (10)
(from 2,4,5-trimethoxybenzaldehyde and 2,4-pentanedione) 48% yield. mp 107−108 °C; ESI
MS m/z 279.2 (M+H)+; 1H NMR (300 MHz, CDCl3): δ 2.15 (3H, s), 3.88 (3H, s), 3.89 (3H,
s), 3.94 (3H, s), 5.66 (H, s), 6.42 (H, d, J= 15.9 Hz), 6.50 (H, s), 7.02 (H, s), 7.89 (H, d, J=15.9
Hz). Anal. (C15H18O5) C, H.
4-Acetyl-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-hepta-4,6-dienoic acid ethyl ester (11)
(from vanillin and ethyl 4-acetyl-5-oxohexanoate) 40% yield. Yellow oil; ESI MS m/z 335.0
(M+H)+; 1H NMR (300 MHz, CDCl3): δ 1.25 (3H, t, J= 7.2 Hz), 2.18 (3H, s), 3.96 (3H, s),
4.13 (2H, quart, J= 7.2 Hz), 5.97 (0.5H, s), 6.67 (H, d, J= 15.9 Hz), 6.94 (H, d, J= 8.1 Hz),
7.06 (H, d, J= 1.8 Hz), 7.14 (H, dd, J=1.8 Hz, J= 8.1 Hz), 7.63 (H, d, J=15.9 Hz). Anal.
(C18H22O6·7/4 H2O) C, H.
5-Hydroxy-1,7-bis-(5-hydroxymethyl-furan-2-yl)-hepta-1,4,6-trien-3-one (12)
2,4-Pentanedione (0.2 ml, 2 mmol) and boric anhydride (100 mg, 1.4 mmol) were dissolved
in 15 ml of EtOAc. The solution was stirred at 70°C for 0.5 h. 5-Hydroxymethyl-2-furaldehyde
(506 mg, 4 mmol) and tributyl borate (1.08 ml, 4 mmol) were added. After stirring for 30 min,
butylamine (0.3 ml, 3 mmol) dissolved in 4 ml of EtOAc was added dropwise over 15 min.
The stirring continued for 5 h at 85 °C. The mixture was then hydrolyzed by adding 8 ml of
1N HCl and stirring for 0.5 h at 60 °C. The organic layer was separated, and the aqueous layer
was extracted with EtOAc. The combined organic layers were washed until neutral, and dried
over anhydrous sodium sulfate. The solvent was removed in vacuo, and the crude product was
purified by CombiFlash® column chromatography eluting with hexane-EtOAc to give 68 mg
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red powder, obtained in 12% yield. mp 129−130 °C; ESI MS m/z 339.2 (M+Na)+; 1H NMR
(300 MHz, CDCl3): δ 4.67 (4H, s), 5.74 (H, s), 6.40 (2H, d, J= 3.3 Hz), 6.53 (2H, d, J= 15.3
Hz), 6.58 (2H, d, J= 3.3 Hz), 7.43 (2H, d, J=15.6 Hz). Anal. (C17H16O6) C, H.
Preparation of heterocycle-containing curcumin analogs 13−15
Compound 5 and boric anhydride (0.7 equiv.) dissolved in EtOAc were stirred at 70 °C for 0.5
h. The appropriate benzaldehyde (1 equiv.) and tributylborate (2 equiv.) were added, and the
mixture was stirred for 0.5 h. Piperidine dissolved in EtOAc was added dropwise. After
increasing the temperature to 100 °C, stirring was continued for 1 h. The mixture was then
hydrolyzed by adding 1N HCl, and stirring at 60 °C for 0.5 h. The organic layer was separated,
and the aqueous layer was extracted with EtOAc three times. The combined organic layers
were washed with water until neutral. The solvent was removed in vacuo. The crude products
were purified by flash column chromatography eluting with hexane-EtOAc.
5-Hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(5-hydroxymethyl-furan-2-yl)-hepta-1,4,6-
trien-3-one (13)
(from 5-hydroxymethyl-2-furaldehyde) 32% yield. mp 140−142°C; ESI MS m/z 343.3 (M
+H)+, 366.2 (M+Na)+; 1H NMR (300 MHz, CDCl3): δ 3.90 (3H, s), 4.64 (2H, s), 5.71 (H, s),
6.36 (H, d, J= 2.7 Hz), 6.43 (H, d, J= 7.5 Hz), 6.47 (H, d, J= 7.2 Hz), 6.53 (2H, d, J= 3.0 Hz),
6.90 (H, d, J= 8.1 Hz), 7.01 (H, s), 7.08 (H, d, J= 7.5 Hz), 7.33 (H, d, = 15.3 Hz), 7.55 (H, d,
J=15.6 Hz). Anal. (C19H18O6) C, H.
5-Hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-thiophen-2-yl-hepta-1,4,6-trien-3-one (14)
(from thiophene-2-carbalydehyde) 38% yield. mp 130−132 °C; ESI MS m/z 327.1
(M-1)+; 1H NMR (300 MHz, CDCl3): δ 3.89 (3H, s), 5.28 (H, s), 5.74 (H, s), 6.37 (H, d, J=
15.6 Hz), 6.45 (H, d, J= 15.9 Hz), 6.91 (H, d, J= 7.8 Hz), 7.01 (H, d, J= 2.4 Hz), 7.02 (H, d,
J= 1.2 Hz), 7.04 (H, s), 7.08 (H, dd, J= 1.2 Hz, J= 7.8 Hz), 7.21 (H, d, J= 3.6 Hz), 7.34 (H, d,
J= 4.8 Hz), 7.57 (H, d, J=15.6 Hz), 7.73 (H, d, J= 15.3 Hz). Anal. (C18H16O4S) C, H.
5-Hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(1H-pyrrol-2-yl)-hepta-1,4,6-trien-3-one (15)
(from 1H-pyrrole-2-carbaldehyde) 24% yield. mp 138−139 °C; ESI MS m/z 334.2 (M
+Na)+; 1H NMR (300 MHz, CD3COCD3): δ 3.92 (3H, s), 5.86 (H, s), 6.25 (H, s), 6.47 (H, d,
J= 15.9 Hz), 6.64 (H, s), 6.68 (H, d, J= 15.9 Hz), 6.88 (H, d, J= 7.8 Hz), 7.06 (H, s), 7.16 (H,
d, J= 7.8 Hz), 7.32 (H, s), 7.57 (H, d, J=15.9 Hz), 7.59 (H, d, J= 15.9 Hz). Anal. (C18H17O4)
C, H, N.
Preparation of symmetric curcumin analogs 16−26
Compounds 16−19 and 22−26 were prepared from corresponding benzaldehydes by using the
same procedure described above for 12 from 5-hydroxymethyl-2-furaldehyde. The preparation
of 20 and 21 was reported elsewhere by us.
5-Hydroxy-1,7-bis-(3-hydroxy-4-methoxyphenyl)-hepta-1,4,6-trien-3-one (16)
(from 3-hydroxy-4-methoxybenzaldehyde and 2,4-pentanedione) 45% yield. mp 181−183 °C
(lit.25 190−192 °C); ESI-MS m/z 367.1 (M-1)+; 1H NMR (300 MHz, CD3COCD3): δ 4.01
(6H, s), 6.01 (H, s), 6.66 (2H, d, J= 15.6 Hz), 7.03 (2H, d, J= 8.1 Hz), 7.20 (2H, dd, J= 2.1 Hz,
J= 8.1 Hz), 7.26 (2H,d, J=2.1 Hz), 7.65 (2H, d, J= 15.3 Hz).
1,7-Bis-(2,4-dimethoxyphenyl)-5-hydroxy-hepta-1,4,6-trien-3-one (17)
(from 2,4-dimethoxybenzaldehyde and 2,4-pentanedione) 48% yield. mp 135−137 °C; ESI-
MS m/z 367.1 (M+1)+; 1H NMR (300 MHz, CD3COCD3): δ 3.87 (12H, s), 5.81 (H, s), 6.46
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(2H,d, J=2.4 Hz), 6.52 (2H, dd, J= 2.4 Hz, J= 8.7 Hz), 6.63 (2H, d, J= 15.6 Hz), 7.49 (2H, d,
J= 8.7 Hz), 7.90 (2H, d, J= 15.9 Hz). Anal. (C23H24O6·1/4 H2O) C, H
5-Hydroxy-1,7-bis-(2,3,4-trimethoxyphenyl)-hepta-1,4,6-trien-3-one (18)
(from 2,3,4-trimethoxybenzaldehyde and 2,4-pentanedione) 30% yield. mp 108−109 °C; ESI
MS m/z 457.2 (M+H)+; 1H NMR (300 MHz, CDCl3): δ 3.89 (6H, s), 3.90 (6H, s), 3.94 (6H,
s), 5.83 (H, s), 6.64 (2H, d, J= 15.9 Hz), 6.71 (2H, d, J= 9 Hz), 7.31 (2H, d, J= 8.7 Hz), 7.85
(2H,d, J=16.2 Hz). Anal. (C25H28O8) C, H.
5-Hydroxy-1,7-bis-(2,4,5-trimethoxyphenyl)-hepta-1,4,6-trien-3-one (19)
(from 2,4,5-trimethoxybenzaldehyde and 2,4-pentanedione) 28% yield. mp 140−142 °C; ESI
MS m/z 457.2 (M+H)+; 1H NMR (300 MHz, CDCl3): δ3.88 (6H, s), 3.94 (6H, s), 5.86 (H, s),
5.57 (2H, d, J= 15.9 Hz), 6.51 (2H, s), 7.06 (2H, s), 7.95 (2H, d, J=15.9 Hz). Anal.
(C25H28O8) C, H.
5-Hydroxy-7-[3-methoxy-4-(tetrahydropyran-2-yloxy)-phenyl]-4-{3-[3-methoxy-4-
(tetrahydropyran-2-yloxy)-phenyl]-acryloyl}-hepta-4,6-dienoic acid ethyl ester (20)
Yellow powder, 59% yield, mp 60− 61 °C; ESI MS m/z 635.2 (M-1)+; 1H NMR (300 MHz,
CDCl3): δ 1.25 (3H, t), 1.57−2.17 (12H, m), 2.96 (0.57H, t), 3.62 (4H, t), 3.91 (6H, s), 4.13
(2H, q), 5.47 (2H, t), 6.72 (2H, d, J=15.6 Hz), 6.90−7.18 (6H, m), 7.44 (2H, d, J=15.6 Hz);
Anal. (C30H32O8) C, H.
5-Hydroxy-1,7-bis-[3-methoxy-4-(tetrahydropyran-2-yloxy)-phenyl]-hepta-1,4,6-trien-3-one
(21)
Yellow powder; 67% yield, mp 67−69 °C; ESI MS m/z 535.0 (M-1)+; 1H NMR (300 MHz,
CDCl3): δ 1.57−2.17 (12H, m), 3.62 (4H, t), 3.91 (6H, s), 5.47 (2H, t), 5.83 (1H, s), 6.50 (2H,
d, J=15.9 Hz), 7.09−7.16 (6H, m), 7.60 (2H, d, J=15.9 Hz); Anal. (C31H36O8·H2O) C, H.
1,7-Bis-(4-ethoxy-3-methoxyphenyl)-5-hydroxy-hepta-1,4,6-trien-3-one (22)
(from 4-ethoxy-3-methoxybenzaldehyde and 2,4-pentanedione) 31% yield, mp 139−140°C
(lit.26 102 °C); ESI-MS m/z 425.1 (M+1)+; 1H NMR (300 MHz, CDCl3): δ 1.49 (6H, t,
J=7.2Hz), 3.93 (6H, s), 4.15 (4H, quart, J=8.4 Hz), 5.82 (H, s), 6.49 (2H, d, J= 15.6 Hz), 6.88
(2H, d, J= 8.1 Hz), 7.08 (2H,d, J=2.1 Hz), 7.14 (2H, dd, J= 2.1 Hz, J= 8.1 Hz), 7.61 (2H, d,
J= 15.6 Hz).
3-Methoxy-4-(3-methyl-but-2-enyloxy)-benzaldehyde
Vanillin (1.52 g, 10 mmol) and anhydrous potassium carbonate (1.38 g, 10 mmol) were
dissolved in dry acetone (20 mL). 1-Bromo-3-methyl-but-2-ene (3.0 mL) was then added to
the solution, and stirring continued for 12 h. The solvent was evaporated in vacuum, and the
resulting solid was extracted with CH2Cl2 three times. The CH2Cl2 solution was washed with
water and dried over anhydrous sodium sulfate. The organic solvent was removed in vacuum.
A colorless liquid (418 mg) was obtained by flash column chromatography eluting with a
gradient hexane-EtOAc solvent. 1H NMR (300 MHz, CDCl3): δ1.76 (3H, s), 1.80 (3H, s), 3.94
(3H, s), 4.68 (2H, d, J=6.6 Hz), 5.52 (H, t, J=6.6 Hz), 6.98 (H, d, J= 8.4 Hz), 7.41 (H,d, J=2.1
Hz), 7.44 (H, dd, J= 2.1 Hz, J= 8.4 Hz), 9.85 (H, s).
5-Hydroxy-1,7-bis-[3-methoxy-4-(3-methyl-but-2-enyloxy)-phenyl]-hepta-1,4,6-trien-3-one
(23)
(from 3-methoxy-4-(3-methyl-but-2-enyloxy)-benzaldehyde and 2,4-pentanedione) 25%
yield, mp 124−125°C; ESI MS m/z 527.2 (M+Na)+; 1H NMR (300 MHz, CDCl3): δ 1.75 (6H,
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s), 1.79 (6H, s), 3.92 (6H, s), 4.63 (4H, d, J=6.6 Hz), 5.52 (2H, t, J=6.6 Hz), 5.82 (H, s), 6.50
(2H, d, J= 15.6 Hz), 6.88 (2H, d, J= 8.4 Hz), 7.08 (2H,d, J=1.8 Hz), 7.12 (2H, dd, J= 1.8 Hz,
J= 8.4 Hz), 7.61 (2H, d, J= 15.9 Hz). Anal. (C31H36O6) C, H.
5-Hydroxy-1,7-bis-(4-hydroxy-3,5-dimethoxyphenyl)-hepta-1,4,6-trien-3-one (24)
(from 4-hydroxy-3,5-dimethoxybenzaldehyde and 2,4-pentanedione) 17% yield, mp 198−199
°C (lit.27 188−190 °C); ESI MS m/z 451.2 (M+Na)+; 1H NMR (300 MHz, CDCl3): 3.94 (6H,
s), 5.80 (H, s), 6.49 (2H, d, J= 15.3 Hz), 6.80 (4H, s), 7.58 (2H, d, J= 15.3 Hz).
5-Hydroxy-1,7-bis-(4-hydroxy-3-methylphenyl)-hepta-1,4,6-trien-3-one (25)
(from 4-hydroxy-3-methylbenzaldehyde and 2,4-pentanedione) 52% yield, mp 217−218 °C;
ESI MS m/z 337.2 (M+1)+; 1H NMR (300 MHz, CDCl3): δ 2.26 (6H, s), 5.81 (H, s), 6.50 (2H,
d, J= 15.9 Hz), 6.86 (2H, d, J= 8.4 Hz), 7.27 (2H,d, J=8.4 Hz), 7.36 (2H, s), 7.58 (2H, d, J=
15.9 Hz). Anal. (C21H20O4·1/4H2O) C, H.
5-Hydroxy-1,7-bis-(4-methoxy-3-methylphenyl)-hepta-1,4,6-trien-3-one (26)
(from 4-methoxy-3-methylbenzaldehyde and 2,4-pentanedione) 55% yield, mp 131−132 °C;
ESI MS m/z 365.1 (M+1)+; 1H NMR (300 MHz, CDCl3): δ 2.24 (6H, s), 3.87 (6H, s), 5.78 (H,
s), 6.49 (2H, d, J= 15.6 Hz), 6.83 (2H, d, J= 8.7 Hz), 7.37 (2H,d, J=8.7 Hz), 7.38 (2H, s), 7.60
(2H, d, J= 15.6 Hz). Anal. (C23H24O4·1/8H2O) C, H.
Preparation of asymmetric curcumin analogs 27−31
By using the same procedure described above for 13−15 from 5, compounds 27−30 were
prepared from 6, and 31 from 11.
1-(3,4-Dimethoxyphenyl)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-hepta-1,4,6-trien-3-one
(27)
(from 6 and vanillin) 55% yield, mp 83−84 °C (lit.17 89−91 °C); ESI-MS m/z 381.1
(M-1)+; 1H NMR (300 MHz, CDCl3): δ 3.94 (9H, s), 5.81 (H, s), 6.48 (2H, d, J= 15.6 Hz),
6.87− 7.14 (6H, m), 7.60 (2H, d, J= 15.6 Hz).
7-(3,4-Dimethoxyphenyl)-5-hydroxy-1-(3-hydroxy-4-methoxyphenyl)-hepta-1,4,6-trien-3-one
(28)
(from 6 and 3-hydroxy-4-methoxybenzaldehyde) 45% yield, mp 157−158°C; ESI-MS m/z
405.3 (M+ Na)+; 1H NMR (300 MHz, CDCl3): δ 3.93 (3H, s), 3.94 (6H, s), 5.80 (H, s), 6.48
(H, d, J= 16.2 Hz), 6.51 (H, d, J= 15.9 Hz), 6.86 (H, d, J= 8.4 Hz), 6.89 (H, d, J= 8.4 Hz), 7.06
(H, dd, J= 8.4 Hz, J= 1.8 Hz), 7.09 (H, d, J= 1.8 Hz), 7.15 (H, dd, J= 8.4 Hz, J= 1.8 Hz), 7.18
(H, d, J= 1.8 Hz), 7.58 (H, d, J= 15.9 Hz), 7.61 (2H, d, J= 15.6 Hz).
1-(3,4-Dimethoxyphenyl)-5-hydroxy-7-(2,3,4-trimethoxyphenyl)-hepta-1,4,6-trien-3-one (29)
(from 6 and 2,3,4-trimethoxybenzaldehyde) 55% yield, mp 138−139 °C; ESI-MS m/z 427.2
(M+H)+, 449.3 (M+Na)+; 1H NMR (300 MHz, CDCl3): δ 3.89(3H, s), 3.91 (3H, s), 3.93 (3H,
s), 3.94 (6H, s), 5.83 (H, s), 6.51 (H, d, J= 15.9 Hz), 6.63 (H, d, J= 15.9 Hz), 6.71 (H, d, J=
8.7 Hz), 6.89 (H, d, J= 8.4 Hz), 7.09 (H, d, J= 2.1 Hz), 7.15 (H, dd, J= 1.8 Hz, J= 8.7 Hz), 7.31
(H, d, J= 8.7 Hz), 7.61 (H, d, J= 15.9 Hz), 7.85 (H, d, J= 16.2 Hz). Anal. (C24H26O7·1/2H2O)
C, H.
1-(3,4-Dimethoxyphenyl)-5-hydroxy-7-(2,4,5-trimethoxyphenyl)-hepta-1,4,6-trien-3-one (30)
(from 6 and 2,4,5-trimethoxybenzaldehyde) 48% yield, mp 128−129 °C; ESI-MS m/z 427.2
(M+H)+, 449.3 (M+Na)+; 1H NMR (300 MHz, CDCl3): δ 3.89(3H, s), 3.90 (3H, s), 3.93 (3H,
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s), 3.94 (3H, s), 3.95 (3H, s), 5.84 (H, s), 6.50 (H, d, J= 15.6 Hz), 6.51(H, s), 6.57 (H, d, J=
16.2 Hz), 6.88 (H, d, J= 8.1 Hz), 7.06 (H, s), 7.08 (H, d, J= 2.1 Hz), 7.14 (H, dd, J= 2.1 Hz,
J= 8.1 Hz), 7.60 (H, d, J= 15.9 Hz), 7.96 (H, d, J= 15.9 Hz). Anal. (C24H26O7·1/4H2O) C, H.
4-[3-(3,4-Dimethoxyphenyl)-acryloyl]-7-(4-hydroxy-3-methoxyphenyl)-5-oxo-hept-6-enoic
acid ethyl ester (31)
(from 11 and 3,4-dimethoxybenzaldehyde) 38% yield, mp 67−68 °C; ESI-MS m/z 483.4 (M
+H)+; 1H NMR (300 MHz, CDCl3): δ 1.25 (3H, t, J= 7.2 Hz), 2.32−2.37 (2H, m), 2.55 (2H,
t, J = 7.8 Hz), 2.95 (0.5H, t, J= 7.8 Hz), 3.91−3.97 (9H, m), 4.14 (2H, q, J = 7.2 Hz), 6.70 (H,
dd, J= 4.2 Hz, J=15.6 Hz), 6.84−7.19 (7H, m), 7.62−7.76 (2H, m); Anal. (C27H30O8·1/4H2O)
C, H.
Preparation of 32, 33 and 34
To a solution of acetone (0.36 ml, 5 mmol) and the appropriate benzaldehyde (10 mmol) in 50
ml of a 0.25 M solution of aqueous NaOH was added 1.5 ml of a 25% w/w aqueous solution
of cetyltrimethylammonium bromide. The mixture was allowed to stir vigorously at room
temperature for 20 h, diluted with brine and extracted with EtOAc. The EtOAc solution was
concentrated and then subjected to column chromatography to obtain the target product.
1,5-Bis-(4-hydroxy-3-methoxyphenyl)-penta-1,4-dien-3-one (32)
50% yield. mp 83−84 °C (lit.25 84−86 °C); ESI MS m/z 327.3 (M+H)+; 1H NMR (300 MHz,
CDCl3): δ 3.94 (6H, s), 6.90 (2H, d, J = 8.4 Hz), 6.95 (2H, d, J= 15.6 Hz), 7.11 (2H, d, J= 1.8
Hz), 7.20 (2H, dd, J= 1.8 Hz, J= 8.4 Hz), 7.68 (2H,d, J=15.6 Hz).
1,5-Bis-(3,4-dimethoxyphenyl)-penta-1,4-dien-3-one (33)
Bright yellow powder. 76% yield; mp 74−75 °C (lit.25 72−75 °C); ESI-MS m/z 355.2 (M
+H)+; 1H NMR (300 MHz, CDCl3); δ 3.86 (3H, s), 3.90 (3H, s), 6.47 (2H, d, J = 2.4 Hz), 6.53
(2H, dd, J= 2.4 Hz, J= 8.4 Hz), 7.09 (2H, d, J= 15.9 Hz), 7.57 (2H, d, J= 8.4 Hz), 7.69 (2H,d,
J=15.9 Hz).
Preparation of 35 and 36
Compounds 35 and 36 were prepared from 4-hydroxy-3-methoxy-cinnamaldehyde by using
the same procedure described above for 12 from 2,4-pentanedione and 5-hydroxymethyl-2-
furaldehyde.
7-Hydroxy-1,11-bis-(4-hydroxy-3-methoxyphenyl)-undeca-1,3,6,8,10-pentaen-5-one (35)
(from 4-hydroxy-3-methoxy-cinnamaldehyde and 2,4-pentanedione) 15% yield; mp 162−164
°C; ESI-MS m/z 421.4 (M+1)+; 1H NMR (300 MHz, CDCl3): † 3.95 (6H, s), 5.78 (H, s), 6.13
(2H, d, J= 15.6 Hz), 6.78−7.04 (10H, m), 7.41 (H, d, J= 15.0 Hz), 7.44 (H, d, J=15.3 Hz). Anal.
(C25H24O6) C, H.
5-Hydroxy-9-(4-hydroxy-3-methoxyphenyl)-4-[5-(4-hydroxy-3-methoxyphenyl)-penta-2,4-
dienoyl]-nona-4,6,8-trienoic acid ethyl ester (36)
(from 4-hydroxy-3-methoxycinnamaldehyde and ethyl 4-acetyl-5-oxohexanoate) 22% yield;
mp 143−144 °C; ESI-MS 519.3 (M-1)−; 1H NMR (300 MHz, CD3COCD3): δ 1.24 (3H, t, J=
7.2 Hz), 2.80−2.86 (4H, m), 3.89 (6H, s), 4.11 (2H, quart, J= 7.2 Hz), 6.78 (2H,d, J=14.4 Hz),
6.85 (2H, d, J= 8.1 Hz), 7.02 (2H, d, J= 15.0 Hz), 7.07 (2H, dd, J= 1.8 Hz, J= 8.1 Hz), 7.26
(2H, d, J= 1.8 Hz), 7.52 (H, d, J= 15.0 Hz), 7.55 (H, d, J= 14.4 Hz). Anal.
(C30H16O4·3/8H2O) C, H.
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Dimethyl curcumin (2) (80 mg, 0.2 mmol) was dissolved in 3 mL of EtOAc. 10% Pd/C (80
mg) was added to the solution. After hydrogenation for 24 h at 45 psi, the solution was filtrated,
and the filtrate was concentrated. Flash column chromatography (hexane/EA= 2:1) afforded
white product in 25% yield. mp 93−94 °C (lit.17 94−95 °C). ESI-MS m/z 425.1 (M+Na)+; 1H
NMR (300 MHz, CDCl3): 1.61−1.85 (2H, m), 2.56−2.87 (8H, m), 3.85 (6H, s), 3.86 (6H, s),
4.07 (H, m), 6.69−6.90 (6H, m).
3,4-Dimethoxycinnamone
3,4-Dimethoxybenzaldehyde (1.5 g, 9 mmol) was dissolved in 10 mL of acetone. After 10 mL
of sodium hydroxide solution (0.5 g NaOH in 10 mL of H2O) was added, the mixture was
stirred for 24 h. Then the excess acetone was removed in vacuo. Upon acidification with 1 N
HCl, a green precipitate was obtained. The precipitate was extracted with EtOAc. The organic
layer was dried over sodium sulfate and solvent removed in vacuo. Flash column
chromatography gave the desired product (1.5 g in 81% yield). 1H NMR (300 MHz,
CD3COCD3): 2.27 (3H, s), 3.87 (6H, s), 6.67 (H, d, J= 16.2 Hz), 7.00 (H, d, J= 8.1 Hz), 7.04
(H, d, J= 0.9 Hz), 7.22 (H, dd, J= 2.1 Hz, J= 8.1 Hz), 7.32 (H, d, J= 2.1 Hz), 7.55 (H, d, J=
16.2 Hz).
3, 4-Dimethoxycinnamaldehyde
To a solution of acetaldehyde (0.84 ml, 15 mmol) in EtOH (10 ml), 3 M NaOH (5ml, 15 mmol)
was added at 0 °C. The solution was stirred for an additional 20 min. After 3, 4-
dimethoxybenzaldehyde (2.5 g, 15 mmol) in EtOH (5 ml) was added to the stirring solution
dropwise, the reaction was brought to room temperature and stirred for 2 h. Then the mixture
was poured into water and adjusted to pH 7 by adding 1N HCl. After extraction with EtOAc,
the organic layer was washed with water three times and dried over anhydrous sodium sulfate.
After removal of the solvent under vacuum, the crude product was purified with flash column
chromatography. Pale yellow product (1.1 g) was obtained in 38% yield. 1H NMR (300 MHz,
CDCl3): δ 3.93 (3H, s), 3.94 (3H, s), 6.62 (H, dd, J= 7.8 Hz, J= Hz), 6.91 (H, d, J= 8.1 Hz),
7.08 (H, d, J= 2.1 Hz), 7.17 (H, dd, J= 1.8 Hz, J= 8.1 Hz), 7.42 (H, d, J= 15.9 Hz), 9.67 (H, d,
J= 7.8 Hz).
1,7-Bis-(3,4-dimethoxyphenyl)-5-hydroxy-hepta-1,6-dien-3-one (38)
To a stirring solution of lithium diisopropylamine (0.29 ml, 0.58 mmol) in THF (3 ml), a THF
(3 ml) solution of 3, 4-dimethoxycinnamone (100 mg, 0.48 mmol) was added at −78 °C. After
15 min, 3,4-dimethoxycinnamaldehyde (85 mg, 0.44 mmol) in THF (3 ml) was added. After
stirring for an additional 20 min at −78 °C, the mixture was quenched with saturated NH4Cl
solution. The solution was allowed to warm to ambient temperature and extracted with EtOAc.
The organic layer was washed with water and saturated NaCl solution and dried over anhydrous
sodium sulfate. The crude product was purified by flash column chromatography to give 22
mg pure product in13% yield. mp 88−89 °C; ESI MS m/z 399.3 (M+H)+; 1H NMR (300 MHz,
CDCl3): δ 2.93 (2H, d), 3.80 (6H, s), 3.85 (6H, s), 4.13 (H, d), 6.25 (H, dd, J= 6Hz, J= 15.9
Hz), 6.58 (H, d, J= 15.9 Hz), 6.80 (H, d, J= 16.2 Hz), 6.88 (H, d, J=8.7 Hz), 6.90 (H, dd, J=
0.9 Hz, J= 8.7 Hz), 7.00 (H, d, J= 8.4 Hz), 7.04 (H, d, J= 0.9 Hz), 7.25 (H, dd, J= 0.9 Hz, J=
8.7 Hz), 7.34 (H, d, J= 0.9 Hz), 7.61 (1H, d, J= 16.2 Hz). Anal. (C23H26O6) C, H.
3-(3,4-Dimethoxyphenyl)-N-[3-(3,4-dimethoxyphenyl)-acryloyl]-acrylamide (39)
3,4-Dimethoxycinnamic acid (624 mg, 3 mmol) was dissolved in 15 mL of dry methylene
chloride. Thionyl chloride (0.3 mL, 3.6 mmol) was added at 0 °C. The solution was stirred
under reflux for 5 h. The solvent was removed under vacuum to give a yellow solid. In the
same flask, 10 mL of anhydrous THF was added, and the mixture heated to reflux. HMDA
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(0.3 mL) was added very slowly to the refluxing solution, followed by the addition of
triethylamine (0.4 mL). The solution was stirred under reflux overnight. The solvent was then
removed in vacuo. The solid was extracted with CH2Cl2 three times. The combined CH2Cl2
solution was washed with water three times and brine once, and then dried over anhydrous
sodium sulfate. The crude product was obtained after flash column chromatography. 78 mg
(13% yield), pale yellow powder. mp 220−221 °C; ESI MS m/z 420.2 (M+Na)+; 1H NMR (300
MHz, DMSO): 3.82 (12H, s), 7.04 (2H, d, J= 8.7 Hz), 7.10 (2H, d, J= 15.9 Hz), 7.23 (2H, s),
7.24 (2H, d, J= 8.7 Hz), 7.66 (2H,d, J=15.9 Hz), 10.51 (0.5 H, s). Anal. (C22H23NO6·3/2H2O)
C, H; N: 2.61.
The preparation of compounds 4, 40−45, 47 and 48 was reported by us in a recent publication.
18
7-(3,4-Dimethoxyphenyl)-4-[3-(3,-dimethoxyphenyl)-acryloyl]-5-hydroxy-hepta-2,4,6-trienoic
acid ethyl ester (4)
Red powder, 54% yield; mp 170 − 171°C; ESI MS m/z 494.6 (M+H)+; 1H NMR (300 MHz,
CDCl3): δ 1.34 (3H, t), 3.95 (12H, s), 4.29 (2H, quart), 5.98 (2H, d, J=15.6 Hz), 6.95 (2H, d,
J= 8.4 Hz), 7.00 (1H, d, J= 15.6 Hz), 7.08 (2H, d, J= 1.8 Hz), 7.22 (2H, dd, J=8.4 Hz, J= 1.8
Hz), 7.77 (2H, d, J= 15.3 Hz), 7.91 (1H, d, J= 15.6Hz). Anal. (C28H30O8·1/4H2O) C, H.
5-Hydroxy-7-[3-methoxy-4-(tetrahydropyran-2-yloxy)-phenyl]-4-{3-[3-methoxy-4-
(tetrahydropyran-2-yloxy)-phenyl]-acryloyl}-hepta-2,4,6-trienoic acid ethyl ester (40)
Orange powder; 62% yield; mp 72− 73 °C; ESI MS m/z 634.7 M+; 1H NMR (300 MHz,
CDCl3): δ 1.34 (3H, t), 1.5−2.2 (12H, m), 3.62 (4H, t), 3.92 (6H, s), 4.28 (2H, q), 5.49 (2H, t)
5.96 (H, d, J=15.6 Hz), 7.00 (2H, d, J= 15.6 Hz), 7.08−7. 16 (6H, m), 7.76 (2H, d, J= 15.3 Hz),
7.83 (H, d, J= 15.9Hz); Anal. (C36H42O10) C, H.
5-Hydroxy-7-(4-hydroxy-3-methoxyphenyl)-4-[3-(4-hydroxy-3-methoxyphenyl)-acryloyl]-
hepta-2,4,6-trienoic acid ethyl ester (41)
Orange powder, 93% yield; mp 106− 106.5 °C; ESI MS m/z 465.2 (M-1)+; 1H NMR (300
MHz, CDCl3): δ 1.34 (3H, t), 3.95 (6H, s), 4.29 (2H, quart), 5.96 (2H, d, J=15.6 Hz), 6.95 (2H,
d, J= 8.2 Hz), 6.96 (1H, d, J= 15.6 Hz), 7.05 (2H, d, J= 2.1 Hz), 7.17 (2H, dd, J=8.2 Hz, J=
2.1 Hz), 7.75 (2H, d, J= 15.3 Hz), 7.90 (1H, d, J= 15.9Hz). Anal. (C26H26O8·11/8H2O) C, H.
7-(3,4-Dimethoxyphenyl)-4-[3-(3,4-dimethoxyphenyl)-acryloyl]-5-hydroxy-hepta-2,4,6-
trienoic acid methyl ester (42)
Orange powder; 50% yield; mp 167−168 °C; ESI MS m/z 481.6 (M+H)+; 1H NMR (300 MHz,
CDCl3): δ 3.82 (3H, s), 3.93 (12H, s), 5.98 (H, d, J=15.6 Hz), 6.90 (2H, d, J= 8.4 Hz), 6.98
(2H, d, J= 15.6 Hz), 7.07 (2H, d, J= 1.8 Hz), 7. 20 (2H, dd, J= 8.4 Hz, J= 1.8 Hz), 7.76 (2H,
d, J= 15.6 Hz), 7.90 (H, d, J= 15.9Hz); Anal. (C27H28O8·1/4H2O) C, H.
7-(3,4-Dimethoxyphenyl)-4-[3-(3,4-dimethoxyphenyl)-acryloyl]-5-hydroxy-hepta-2,4,6-
trienoic acid ethylamide (43)
Yellow powder, 16% yield; mp 219−221 °C; ESI MS m/z 516.2 (M+Na)+; 1H NMR (300 MHz,
CDCl3): δ 1.32 (3H, t), 3.92 (6H, s), 3.92 (6H, s), 4.00 (2H, quart), 5.85(H, d, J=15.3 Hz), 6.88
(2H, d, J= 8.4 Hz), 6.95 (2H, d, J= 15.6 Hz), 7.06 (2H, d, J= 1.5 Hz), 7.18 (2H, dd, J= 8.4 Hz,
J= 1.5 Hz), 7.73 (2H, d, J= 15.6 Hz), 7.82(H, d, J= 15.3Hz); Anal. (C28H31NO7·3/2H2O) C,
H.
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19% yield; mp 204−205 °C; ESI MS m/z 448.3 (M+H)+; 1H NMR (300 MHz, DMSO): δ 3.70
(3H, s), 3.75 (3H, s), 3.79 (3H, s), 3.80 (3H, s), 6.32 (H, d, J=9.6 Hz), 6.99 (2H, dd, J= 8.4 Hz,
J= 1.5 Hz), (2H, d, J= 15.6 Hz), (2H, d, J= 1.8 Hz), (2H, dd, J= 8.4 Hz, J= 1.8 Hz), (2H, d,
J= 15.6 Hz), (H, d, J= 15.9Hz); Anal. (C26H25NO6·9/4H2O) C, H.
1,7-Bis-(3,4-dimethoxyphenyl)-5-hydroxy-4-(3-hydroxypropenyl)-hepta-1,4,6-trien-3-one
(45)
Red powder. 19% yield; mp 178−179 °C; ESI MS m/z 453.2 (M+Na)+; 1H NMR (300 MHz,
CDCl3): 3.92 (6H, s), 3.93 (6H, s), 4.40 (2H, d, triplet of doublet, J= 4.5 Hz), 5.30 (0.4 H, s),
5.88 (H, J=15.6 Hz, J= 4.5 Hz), 6.59 (H, d, J= 15.6 Hz), 6.88 (2H, d, J= 8.4 Hz), 6.97 (2H, d,
J= 15.6 Hz), 7.06 (2H, d, J= 1.8 Hz), 7.17 (2H, dd, J= 8.4 Hz, J= 1.8 Hz), 7.68 (2H, d, J= 15.6
Hz); Anal. (C26H28O7·3/4H2O) C, H.
3-[1-Hydroxy-3-(4-hydroxy-3-methoxyphenyl)-allylidene]-6-(4-hydroxy-3-methoxyphenyl)-
hex-5-ene-2,4-dione (46)
Compound 46 was obtained from vanillin and triacetylmethane by using the same procedure
described above for 12 from 5-hydroxymethyl-2-furaldehyde and 2,4-pentanedione. 8% yield;
mp 162−164 °C; ESI MS m/z 433.2 (M+Na)+; 1H NMR (300 MHz, CDCl3): δ 2.17 (3H, s),
3.94 (6H, s), 5.80 (H, s), 6.48 (2H, d, J= 15.6 Hz), 6.94 (2H, d, J= 8.1 Hz), 7.05 (2H,d,2H, d,
J=1.8 Hz), 7.13 (2H, dd, J= 1.8 Hz, J= 8.1 Hz), 7.59 (2H, d, J= 15.6 Hz). Anal. (C23H22O7)
C, H.
4-Fluoro-7-[3-methoxy-4-(tetrahydropyran-2-yloxy)-phenyl]-4-{3-[3-methoxy-4-
(tetrahydropyran-2-yloxy)-phenyl]-acryloyl}-5-oxo-hept-6-enoic acid ethyl ester (47)
13% yield; mp 59− 60 °C; EIMS m/z 677.3 (M+Na)+, 655.3 (M+H)+; 1H NMR (300 MHz,
CDCl3): δ 1.25 (3H, t), 1.5−2.1 (12H, m), 2.45(2H, m), 2.65 (2H, m), 3.62 (4H, t), 3.90 (6H,
s), 4.13 (2H, q), 5.49 (2H, t), 7.06 (2H, dd, J=3 Hz, J=15.6 Hz), 7.12−7.15 (6H, m), 7.75 (2H,
d, J=15.6 Hz); Anal. (C36H44FO10) C, H.
4-Fluoro-7-(4-hydroxy-3-methoxyphenyl)-4-[3-(4-hydroxy-3-methoxyphenyl)-acryloyl]-5-
oxo-hept-6-enoic acid ethyl ester (48)
97% yield; mp 63− 63.5 °C; EIMS m/z 509.3 (M+Na)+, 487.3 (M+H)+; 1H NMR (300 MHz,
CDCl3): δ 1.25 (3H, t), 2.45(2H, m), 2.65 (2H, m), 3.95 (6H, s), 6.93 (2H, d, J=7.8 Hz), 7.06
(2H, dd, J= 3 Hz, J=15.6 Hz), 7.09(2H, d, J= 1.8 Hz), 7.16 (2H, dd, J=1.8 Hz, J=7.8 Hz), 7.75
(2H, d, J=15.6 Hz); Anal. (C26H27FO8·3/4H2O) C, H.
1,7-Bis-(3,4-dimethoxyphenyl)-4-methyl-hepta-1,6-diene-3,5-dione (49)
Compound 49 was prepared from 3-methyl-2,4-pentanedione and 3,4-dimethoxybenzaldehyde
by using the same procedure described above for 12 from 2,4-pentanedione and 5-
hydroxymethyl-2-furaldehyde. 51% yield; mp 129−130 °C (lit.28 142−145 °C); ESI MS m/z
433.2 (M+Na)+; 1H NMR (300 MHz, CDCl3): δ 2.19 (3H, s), 3.91 (3H, s), 3.93 (3H, s), 3.95
(3H, s), 6.89 (2H, d, J=8.1 Hz), 6.99 (2H, d, J=15.3 Hz), 7.10 (2H, d, J=1.8 Hz), 7.19(2H, dd,
J= 8.1Hz, J=1.8 Hz), 7.70 (2H, d, J=15.6 Hz).
1,7-Bis-(3,4-dimethoxyphenyl)-4-fluoro-4-methyl-hepta-1,6-diene-3,5-dione (50)
Yellow powder. 48% yield; mp 44−45 °C; ESI MS m/z 451.2 (M+Na)+; 1H NMR (300 MHz,
CDCl3): δ 1.97 (3H, s), 3.90 (6H, s), 3.95 (6H, s), 6.83 (2H, d, J=7.8 Hz), 6.87 (2H, dd, J=3
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Hz,J=15.6 Hz), 6.90(2H, d, J= 1.8 Hz), 6.95 (2H, dd, J=1.8 Hz, J=7.8 Hz), 7.75 (2H, d, J=15.6
Hz); Anal. (C24H25FO6·5/2H2O) C, H.
Cytotoxicity bioassay in human prostate cancer cell lines LNCaP and PC-3
The in vitro cytotoxicity bioassay was performed according to the procedures described in
Rubinstein et al.29 Drug stock solutions were prepared in DMSO, and the final solvent
concentration was not greater than 1% DMSO (v/v), a concentration without effect on cell
replication. The human prostate cancer cells were exposed to doses of the compounds for 2
days and variation between replicate experiments was ≤5%. The IC50 values were determined
from dose-response graphs.
Antiandrogenic bioassay in human prostate cancer cells
Human prostate cancer LNCaP and PC-3 cells were maintained in RPMI medium and
Dulbecco's minimum essential medium (DMEM), respectively. Both media were
supplemented with penicillin (25 units/mL), streptomycin (25 μg/mL), and 10% fetal calf
serum. For the androgen receptor transactivation assay, an androgen-dependent reporter gene
transcription test was employed as the primary screening for potential antiandrogen
identification. This assay was first performed in LNCaP cells, which express a clinically
relevant mutant AR. Once anti-androgenic activity was detected in the LNCaP AR
transactivation assay, compounds were re-examined for their potential activity against wild
type AR. Wild type AR transactivation assay was performed in PC-3 host cells, which lack an
endogenous, functional AR. The method and conditions of cell and gene transfection have been
described previously. In brief, cells were plated in 24-well tissue culture dishes for 24 (PC-3
cells) or 48 (LNCaP cells) h prior to transfection. Subsequently, LNCaP cells were transfected
with a reporter gene, MMTV-luciferase, which contains MMTV-LTR promoter and androgen
receptor binding element, and PRL-SV40, which served as an internal control for transfection
efficiency. PC-3 cells were transfected with a wild type AR expression plasmid, pSG5AR, in
addition to the above-mentioned MMTV-luciferase reporter gene and PRL-SV40 internal
control. SuperFect (Qiagen, Chatsworth, CA) was employed as the transfection reagent
following manufacturer's recommendations. At the end of a five-hour transfection, the medium
was changed to DMEM or RPMI supplemented with 10% charcoal dextran-stripped, i.e.,
androgen-depleted, serum. After 24 h, the cells were treated with 1 nM of DHT and/or test
compounds at the designated concentration for another 24 h. The cells were harvested for
luciferase activity assay using Dual Luciferase Assay System (Promega, Madison, WI). The
derived data were expressed as relative luciferase activity normalized to the internal luciferase
control. Cells cultured in medium containing DHT (androgen), as a positive control, induced
a marked reporter gene expression. Test compounds capable of significantly suppressing this
DHT-induced reporter gene expression were identified as potential antiandrogens.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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The general synthetic method for monophenyl curcumin analogs
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The general synthetic strategies for symmetric curcumin analogs
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The general synthetic scheme for asymmetric curcumin analogs
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The general synthetic method of 1, 5-diphenyl-1, 4-pentadien-3-ones
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The synthesis of curcumin analogs having a long linker
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The preparation of 37 from DMC
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The synthesis of 38
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The synthesis of imide analog 39
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The synthesis of 49 and 50
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Structures of curcumin (1), DMC(2), ECECur(3) and 4
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Table 2
The antiandrogenic activity of compounds 3, 4, 40 and 44.
DHT (1 nM) + tested compounds LNCaP transactivation (%) PC3+wt. AR transactivation (%)
DHT (Control) 100 100
DHT+ HF (5 μM) 65 31
DHT+ 3 (5 μM) 4 13
DHT+ 4 (5 μM) 6 40
DHT+ 40 (3 μM) 54 46
DHT+ 44 (5 μM) 42 68
LNCaP and PC-3 human prostate cell lines were seeded and cotransfected with reporter MMTV-luciferase (both cell lines), wild-type AR expression
plasmid (PC-3) using SuperFect. Subsequently, the transfected cells were harvested and re-plated in 10% charcoal-stripped fetal bovine serum DMEM
medium. The cells were then treated with dehydrotestosterone (DHT, 1 nM), and tested compounds (3 μM or 5 μM) and harvested for detection of the
luciferase activity. (cf. Experimental).
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